Publications (14 results)
Please use discretion when following external links; Assaypro cannot guarantee the validity and security of all citation links provided.Distinct patterns of apolipoprotein C-I, C-II, and C-III isoforms are associated with markers of Alzheimer's disease
Examination of external and internal factors for the pathophysiology of pediatric idiopathic steroid-sensitive nephrotic syndrome
Protective effect of inulin and the integrity of the microvasculature in diabetes mellitus
Apolipoprotein C-I Levels Are Associated with the Urinary Protein/Urinary Creatinine Ratio in Pediatric Idiopathic Steroid-Sensitive Nephrotic Syndrome: A Case Control Study
Automated Multiplex LC-MS/MS Assay for Quantifying Serum Apolipoproteins A-I, B, C-I, C-II, C-III, and E with Qualitative Apolipoprotein E Phenotyping
Plasma proteomic analysis of stable coronary artery disease indicates impairment of reverse cholesterol pathway
A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach
MALDI-Based Serum Peptide Signature Discriminating Stomach and Pancreas Adenocarcinoma Patients from Cancer-Free Controls: Adjustment to Diagnosis with Immuno-Based Assays
The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis
Serum Apolipoproteins C-I and C-III Are Reduced in Stomach Cancer Patients: Results from MALDI-Based Peptidome and Immuno-Based Clinical Assays
Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis
* Yan LR et al. (2014) A Pro-Atherogenic HDL Profile in Coronary Heart Disease Patients: An iTRAQ Labelling-Based Proteomic Approach. PLoS One. 9(5):e98368. doi: 10.1371/journal.pone.0098368. eCollection 2014
* Hansen JB et al. (2011) The Apolipoprotein C-I Content of Very-Low-Density Lipoproteins Is Associated with Fasting Triglycerides, Postprandial Lipemia, and Carotid Atherosclerosis. J Lipids. 2011:271062.
* Xue A et al. (2010) Discovery of serum biomarkers for pancreatic adenocarcinoma using proteomic analysis. Br. J. Cancer 103(3):391-400